News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 650 results
March 2017
-
Media Release
Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
- 94% of patients regained their PASI 75 response and the majority re-achieved their PASI 90 or 100 response after 16 weeks of Cosentyx 300 mg retreatment(1)- Patients may need to pause treatment due… -
Media Release
Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
December 2016
-
Media Release
Alcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients
- New intraocular lens (IOL) combines two technologies that correct for presbyopia and corneal astigmatism simultaneously- This IOL is a new option for patients who desire good near, intermediate and… -
Media Release
Alcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients
-
Media Release
Novartis out-licenses three COPD products in the US
Sunovion assumes US commercialization rights for Utibron™ Neohaler®, Seebri™ Neohaler® and Arcapta® NeohalerNovartis will continue to manufacture these important medicines for SunovionIn line with… -
Media Release
Novartis out-licenses three COPD products in the US
-
Media Release
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
- 82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA)- ELIANA, the first global CAR T cell… -
Media Release
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
November 2016
-
Media Release
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril (1)These… -
Media Release
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
-
Media Release
Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
This is the latest addition to the Alcon AIR OPTIX® portfolio of monthly replacement contact lenses which merges two unique technologiesSmartShield® Technology provides excellent deposit resistance… -
Media Release
Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
Pagination
- ‹ Previous page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- …
- 55
- › Next page